cells:研究发现补铁可通过增强线粒体功能延缓衰老并延长寿命

2022-11-10 “ Aging”公众号 “ Aging”公众号

铁是一种重要的营养素,对包括人类在内的几乎所有生物都是必不可少的。它在细胞代谢中起着至关重要的作用,并作为多种酶促反应的辅助因子发挥作用。

世界范围内的人口老龄化现象正在急剧增长,衰老被认为是一些慢性疾病的最大危险因素,如癌症、神经退行性变疾病、心脏病、糖尿病等。

代谢功能的逐渐下降增加了老年人患与年龄相关的疾病的风险,这些疾病也影响了老年人的生活质量

铁是一种重要的营养素,对包括人类在内的几乎所有生物都是必不可少的。它在细胞代谢中起着至关重要的作用,并作为多种酶促反应的辅助因子发挥作用。细胞代谢是衰老的主要决定因素,而铁对几种不同的代谢功能至关重要,但补充铁是否会延缓衰老目前尚不清楚。

近期,来自新加坡的科学家在cells 杂志发表题为”Iron Supplementation Delays Aging and Extends Cellular Lifespan through Potentiation of Mitochondrial Function“的文章,该文章发现补铁可通过增强线粒体功能延缓衰老并延长寿命。

研究人员将细胞与不同浓度的FeSO4孵育在培养基中,并在不同时间点(16 h、24 h和48 h)进行生长分析。在与FeSO4浓度孵育后约24h,细胞生长达到饱和,随后测定了不同浓度FeSO4孵育细胞的CLS,结果表明在培养基中添加不同浓度的FeSO4可以延长酵母的CLS。研究人员还测试了FeCl3,发现结果与FeSO4相似。总之这些结果证实补铁可以延长酵母的寿命。

众所周知线粒体是铁利用和代谢的主要细胞中枢,线粒体功能下降与衰老息息相关。铁是几种线粒体蛋白质的辅助因子,包括铁硫簇和含血红素的蛋白质。

随后研究人员想知道通过补充铁来延长细胞寿命是否需要线粒体功能,为了测试这一点,研究人员分析了线粒体TCA循环基因的表达,发现补铁显着诱导了几种TCA循环基因的表达。TCA循环代谢物α-酮戊二酸和草酰乙酸可通过线粒体中的催化反应产生谷氨酸和天冬氨酸。这些氨基酸用于蛋白质、脂质和核苷酸的生物合成。总之,这些结果表明补铁使细胞处于一种有利于再生的代谢状态,从而促进TCA循环。

总而言之,铁是一种重要的营养物质,涉及多种生物功能,包括新陈代谢。在这项使用酵母作为衰老模型生物的研究中,发现补铁可以延缓衰老并延长细胞寿命。进一步研究表明补铁可上调线粒体三羧酸 (TCA) 循环和电子传递链 (ETC) 基因的表达。

原始出处:

Jovian Lin Jing, et al. Iron Supplementation Delays Aging and Extends Cellular Lifespan through Potentiation of Mitochondrial Function. Cells 2022, 11(5), 862; https://doi.org/10.3390/cells11050862.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2099649, encodeId=204c2099649be, content=研究结果到临床转化有巨大的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:03:20 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099648, encodeId=66f12099648f1, content=希望人体研究有同样结论, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:00:38 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099647, encodeId=bfc7209964e1a, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:56 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099646, encodeId=fd512099646e7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:52 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099645, encodeId=98f32099645e2, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:47 CST 2022, time=2022-11-10, status=1, ipAttribution=)]
    2022-11-10 delianjihui

    研究结果到临床转化有巨大的差距

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2099649, encodeId=204c2099649be, content=研究结果到临床转化有巨大的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:03:20 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099648, encodeId=66f12099648f1, content=希望人体研究有同样结论, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:00:38 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099647, encodeId=bfc7209964e1a, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:56 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099646, encodeId=fd512099646e7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:52 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099645, encodeId=98f32099645e2, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:47 CST 2022, time=2022-11-10, status=1, ipAttribution=)]
    2022-11-10 delianjihui

    希望人体研究有同样结论

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2099649, encodeId=204c2099649be, content=研究结果到临床转化有巨大的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:03:20 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099648, encodeId=66f12099648f1, content=希望人体研究有同样结论, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:00:38 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099647, encodeId=bfc7209964e1a, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:56 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099646, encodeId=fd512099646e7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:52 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099645, encodeId=98f32099645e2, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:47 CST 2022, time=2022-11-10, status=1, ipAttribution=)]
    2022-11-10 delianjihui

    转发学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2099649, encodeId=204c2099649be, content=研究结果到临床转化有巨大的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:03:20 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099648, encodeId=66f12099648f1, content=希望人体研究有同样结论, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:00:38 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099647, encodeId=bfc7209964e1a, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:56 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099646, encodeId=fd512099646e7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:52 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099645, encodeId=98f32099645e2, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:47 CST 2022, time=2022-11-10, status=1, ipAttribution=)]
    2022-11-10 delianjihui

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2099649, encodeId=204c2099649be, content=研究结果到临床转化有巨大的差距, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:03:20 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099648, encodeId=66f12099648f1, content=希望人体研究有同样结论, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 14:00:38 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099647, encodeId=bfc7209964e1a, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:56 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099646, encodeId=fd512099646e7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:52 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099645, encodeId=98f32099645e2, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Thu Nov 10 13:59:47 CST 2022, time=2022-11-10, status=1, ipAttribution=)]
    2022-11-10 delianjihui

    学习受益

    0

相关资讯

Neurology:社会经济地位、衰老(生物)和记忆在美国老年男性和女性多样化的全国样本中

暴露于社会经济劣势与早发性认知老化有关。在一个全国性的中老年人样本中,衰老(生物)的 DNA 甲基化测量与白人、黑人和拉丁裔中老年人的记忆轨迹和 SES 有不同的相关性。

eLife封面:吕宇轩博士发现明星药物雷帕霉素延缓衰老的新靶点

目前认为雷帕霉素通过调节mTOR信号通路从而达到延缓衰老的效果。但是,雷帕霉素作为药物,其可能的药物副作用阻碍其在延缓衰老方面的应用。

34岁不仅是“职场赛点”,也是“断崖式衰老”的开端,60岁和78岁更是大坎!

村上春树有一句名言:“我一直以为人是慢慢变老的,其实不是,人是一瞬间变老的。”

Nature:PD-L1/PD-1阻断疗法,不仅能抗癌,还能抗衰老

近年来,免疫系统紊乱被认为是衰老的一个重要生理特征,有研究报道,癌基因诱导的衰老肝细胞和损伤诱导的衰老星状细胞分别被激活的T细胞和自然杀伤(NK)细胞清除。

Endocrinology:生长激素可能会促进衰老!反之会延长寿命

生长激素的最重要作用是调节生长,然而,它的存在既有好处也有坏处。生长激素存在于人体的许多组织中,在包括衰老在内的许多生物功能中发挥着重要作用。

宣武医院王培昌教授团队发文,揭示衰老细胞基因组全景观变化!

首次系统揭示衰老阶段的全基因组变化景观,识别在体内负责转录时间调控的关键元素,从而为衰老分子机制的解析提供了新的方向。